Supporting your GLP-1 journey. Real stories, tips & advice, UK drug prices compared.
Free Sign Up
SlimrChat is the brainchild of Robert, who is the founder and long-time member of the “genetically plump” club. Like many people, he has spent years juggling a love of food, busy work life and the constant challenge of keeping his weight under control.
Now 58, Robert knows that managing weight does not get easier with age. Slower metabolism, work pressures and social life can make the whole thing feel like an uphill struggle. And after knee replacement surgery in 2024, he suddenly had time to stop and think seriously about his long-term health, including high blood pressure and cholesterol.
At the same time, the news was full of headlines about the new GLP-1 weight loss medications such as Mounjaro and Wegovy, but the coverage rarely felt helpful. It was often alarmist about side effects, obsessed with celebrities, or dismissive and judgy of people using the treatment.
Robert started Mounjaro October 2024 and over around ten months lost around 20kg. The treatment has been genuinely life-changing. He is fitter, thinner and, as he likes to say, relentlessly happier. Like most people on the journey, he has also experienced side effects and the reality that maintaining weight loss still requires effort, discipline and support.
SlimrChat was created because Robert could not find one place that brought together practical information, real experiences and honest conversation about GLP-1 treatment. A place where people could ask questions, compare notes, share wins and talk openly without judgement.
Today he remains passionate about helping others navigate their own journeys with these medications. He still loves food, especially classics like bread and cheese, and the occasional beer! He definitely still enjoys being social and firmly believes that people should have access to good information and supportive communities when making decisions about their health.
SlimrChat exists to be the space he wishes he had when he started.